Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT04340817
Recruiting Observational

Fatty Liver Disease in Nordic Countries

NCT04340817 · tracked via the Priya Life Science Denmark tracker
Sponsor
Copenhagen University Hospital, Hvidovre
Phase
Observational
Started
2017-09-01
Last updated
2020-04-13

Condition(s) studied

Non-Alcoholic Fatty Liver Disease

Investigational drug(s) / intervention(s)

ProteomicsTranscriptomicsGenomics

Proteomics: Mass-spectometry proteomics

Transcriptomics: Next generation sequencing

Genomics: Targeted genetics

Study summary

A prospective cohort study, which aims to systematically evaluate biomarkers and potential targets in NAFLD and NASH.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Non-alcoholic fatty liver disease and * Healthy volunteers Exclusion Criteria: * Other liver diseases than non-alcoholic fatty liver disease * Lack of informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Gastrounit, Copenhagen University Hospital Hvidovre Hvidovre Capital Region Denmark Recruiting

More Copenhagen University Hospital, Hvidovre trials in Denmark

Changes in Perioperative Blood Volume and Fluid Distribution in Patients Undergoing Primary Total Hip Replacement. Recruiting
Optimized Remission in Alcohol-related Liver Cirrhosis Recruiting
The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance Recruiting
Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD Active, not recruiting
Virus as Treatment of C. Difficile Infection (VISION) Starting soon

Other trials for the same condition

Identification of Liver Fibrosis Biomarkers Recruiting
Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals Recruiting
Direct Versus Indirect Effect of Amino Acids on Hepatokines Active, not recruiting
Prognostic Significance of Fatty Liver Disease in Bariatric Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04340817 on ClinicalTrials.gov ↗ ← All trials in Denmark